Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping
NCT06244082 · View on ClinicalTrials.gov ↗
Study Summary
AOC 1044-CS2 (EXPLORE44-OLE) is an Open-label Study to Evaluate the Long-Term Safety and Tolerability of AOC 1044 Administered Intravenously to DMD Participants with Mutations Amenable to Exon 44 Skipping.
Conditions Studied
Interventions
- DRUG AOC 1044
Study Locations (10)
California
- University of California, San Diego, Rady's Children's Hospital — La Jolla
- UC Davis Medical Center — Sacramento
- Lucille Packard Children's Hospital at Stanford — San Carlos
Arkansas
- Arkansas Children's Hospital — Little Rock
Georgia
- Rare Disease Research - Atlanta — Atlanta
Massachusetts
- University of Massachusetts Medical School — Worcester
Minnesota
- Gillette Children's Specialty Healthcare — Saint Paul
North Carolina
- Rare Disease Research — Hillsborough
Ohio
- Abigail Wexner Research Institute at Nationwide Children's Hospital — Columbus
Texas
- Neurology Rare Disease Center — Denton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2024-01-22 |
| Est. Completion | 2027-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06244082
The ClinicalTrials.gov registry entry for NCT06244082 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avidity Biosciences, which has 6 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 1 intervention — of which AOC 1044 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06244082 reports 10 study locations spanning 8 distinct geographic areas — top geographies include California, Arkansas, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06244082 about?
NCT06244082 is a clinical study titled "Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping". AOC 1044-CS2 (EXPLORE44-OLE) is an Open-label Study to Evaluate the Long-Term Safety and Tolerability of AOC 1044 Administered Intravenously to DMD Participants with Mutations Amenable to Exon 44 Skipping.
What is the current status of trial NCT06244082?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2024-01-22. Estimated completion is 2027-07-31.
What conditions does trial NCT06244082 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy, DMD, Exon 44, Duchenne. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06244082?
The interventions under investigation include: AOC 1044 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06244082?
This trial is sponsored by Avidity Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06244082 being conducted?
This trial has 10 study locations across Arkansas, California, Georgia, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.